Short-term safety, tolerability and efficacy of a very low-calorie-ketogenic diet interventional weight loss program versus hypocaloric diet in patients with type 2 diabetes mellitus
- PMID: 27643725
- PMCID: PMC5048014
- DOI: 10.1038/nutd.2016.36
Short-term safety, tolerability and efficacy of a very low-calorie-ketogenic diet interventional weight loss program versus hypocaloric diet in patients with type 2 diabetes mellitus
Abstract
Brackground:The safety and tolerability of very low-calorie-ketogenic (VLCK) diets are a current concern in the treatment of obese type 2 diabetes mellitus (T2DM) patients.
Objective: Evaluating the short-term safety and tolerability of a VLCK diet (<50 g of carbohydrate daily) in an interventional weight loss program including lifestyle and behavioral modification support (Diaprokal Method) in subjects with T2DM.
Methods: Eighty-nine men and women, aged between 30 and 65 years, with T2DM and body mass index between 30 and 35 kg m(-)(2) participated in this prospective, open-label, multi-centric randomized clinical trial with a duration of 4 months. Forty-five subjects were randomly assigned to the interventional weight loss (VLCK diet), and 44 to the standard low-calorie diet.
Results: No significant differences in the laboratory safety parameters were found between the two study groups. Changes in the urine albumin-to-creatinine ratio in VLCK diet were not significant and were comparable to control group. Creatinine and blood urea nitrogen did not change significantly relative to baseline nor between groups. Weight loss and reduction in waist circumference in the VLCK diet group were significantly larger than in control subjects (both P<0.001). The decline in HbA1c and glycemic control was larger in the VLCK diet group (P<0.05). No serious adverse events were reported and mild AE in the VLCK diet group declined at last follow-up.
Conclusions: The interventional weight loss program based on a VLCK diet is most effective in reducing body weight and improvement of glycemic control than a standard hypocaloric diet with safety and good tolerance for T2DM patients.
Conflict of interest statement
AG, DB, BM, ABC and FFC received advisory board fees and or research grants from Pronokal Protein Supplies Spain.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5048014/bin/nutd201636f1.gif)
Similar articles
-
Ketogenic Diet Benefits to Weight Loss, Glycemic Control, and Lipid Profiles in Overweight Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trails.Int J Environ Res Public Health. 2022 Aug 22;19(16):10429. doi: 10.3390/ijerph191610429. Int J Environ Res Public Health. 2022. PMID: 36012064 Free PMC article. Review.
-
Effect of a very low-carbohydrate ketogenic diet vs recommended diets in patients with type 2 diabetes: a meta-analysis.Nutr Rev. 2022 Feb 10;80(3):488-502. doi: 10.1093/nutrit/nuab040. Nutr Rev. 2022. PMID: 34338787
-
The management of very low-calorie ketogenic diet in obesity outpatient clinic: a practical guide.J Transl Med. 2019 Oct 29;17(1):356. doi: 10.1186/s12967-019-2104-z. J Transl Med. 2019. PMID: 31665015 Free PMC article. Review.
-
Acid-base safety during the course of a very low-calorie-ketogenic diet.Endocrine. 2017 Oct;58(1):81-90. doi: 10.1007/s12020-017-1405-3. Epub 2017 Sep 15. Endocrine. 2017. PMID: 28914421 Free PMC article. Clinical Trial.
-
Comparison of a very low-calorie-ketogenic diet with a standard low-calorie diet in the treatment of obesity.Endocrine. 2014 Dec;47(3):793-805. doi: 10.1007/s12020-014-0192-3. Epub 2014 Mar 4. Endocrine. 2014. PMID: 24584583 Clinical Trial.
Cited by
-
The role of cognitive restraint savings and the safety of ketogenic weight loss interventions.Rev Assoc Med Bras (1992). 2024 May 3;70(4):e20231505. doi: 10.1590/1806-9282.20231505. eCollection 2024. Rev Assoc Med Bras (1992). 2024. PMID: 38716951 Free PMC article. No abstract available.
-
Effect of Ketogenic Diet on Obesity and Other Metabolic Disorders: Narrative Review.Diabetes Metab Syndr Obes. 2024 Mar 21;17:1391-1401. doi: 10.2147/DMSO.S447659. eCollection 2024. Diabetes Metab Syndr Obes. 2024. PMID: 38529169 Free PMC article. Review.
-
The impact of ketogenic diet on some metabolic and non-metabolic diseases: Evidence from human and animal model experiments.Food Sci Nutr. 2024 Jan 8;12(3):1444-1464. doi: 10.1002/fsn3.3873. eCollection 2024 Mar. Food Sci Nutr. 2024. PMID: 38455178 Free PMC article. Review.
-
Behavioral Lifestyle Interventions for Weight Loss in Overweight or Obese Patients with Type 2 Diabetes: A Systematic Review of the Literature.Curr Obes Rep. 2024 Jun;13(2):224-241. doi: 10.1007/s13679-024-00552-5. Epub 2024 Mar 4. Curr Obes Rep. 2024. PMID: 38436787 Free PMC article. Review.
-
Ketogenic nutritional therapy (KeNuT)-a multi-step dietary model with meal replacements for the management of obesity and its related metabolic disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-diet therapies in endocrinology and metabolism.J Endocrinol Invest. 2024 Mar;47(3):487-500. doi: 10.1007/s40618-023-02258-2. Epub 2024 Jan 18. J Endocrinol Invest. 2024. PMID: 38238506 Free PMC article.
References
-
- Norris SL, Zhang X, Avenell A, Gregg E, Brown TJ, Schmid CH et al. Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev 2005. CD004095. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical